Skip to main content

Table 1 Preoperative and intraoperative data on the two patient groups

From: Benefits of sacubitril/valsartan use in patients with chronic heart failure after cardiac valve surgery: a single-center retrospective study

Valuables

Group A(n = 172)

Group B(n = 87)

P value

Valve diseases *

   

 Mitral stenosis(n, %)

53 (30.81)

33 (37.93)

0.251

 Mitral insufficiency(n, %)

75(43.60)

38 (43.68)

0.991

 Aortic stenosis(n, %)

66(38.37)

40 (45.98)

0.240

 Aortic insufficiency(n, %)

68(39.53)

32 (36.78)

0.667

 Tricuspid insufficiency(n, %)

58(33.72)

30 (34.48)

0.903

Preoperative EF (%)

60.73 ± 6.37

60.08 ± 8.25

0.523

Surgical procedure

   

 Aortic valve

41 (23.84)

23 (26.44)

0.852

 Mitral valve

55 (31.98)

21 (24.14)

0.417

 Tricuspid valve

5 (2.91)

2 (2.30)

0.954

 Combined valvular surgery

71 (41.27)

41 (47.12)

0.537

Surgical data

   

 Operative time (min)

149.73 ± 34.34

147.01 ± 36.05

0.554

 Circulation bypass time(min)

70.55 ± 19.56

72.63 ± 20.09

0.424

 Aortic Clamp time (min)

37.59 ± 6.37

37.82 ± 14.28

0.900

  1. Continuous variables were present as mean ± SD or median and inter-quartile range, and the counts were expressed as a percentage.Chi-square test for categorical variables and t test or wilcoxon rank sum test for continuous variables. The following tables show the same expression
  2. *Valve diseases was defined as moderate or severe valve stenosis or regurgitation